Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
2006-09-26
2006-09-26
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
3,10-dihydroxy-2-naphthacene carboxamide or derivative doai
Reexamination Certificate
active
07112578
ABSTRACT:
Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.
REFERENCES:
patent: 3255079 (1966-06-01), Schroeder et al.
patent: 4049824 (1977-09-01), Diehl
patent: 4113881 (1978-09-01), Diehl
patent: 5196205 (1993-03-01), Borody
patent: 5260066 (1993-11-01), Wood et al.
patent: 5308839 (1994-05-01), Golub
patent: 5569676 (1996-10-01), Diehl
patent: 5688516 (1997-11-01), Raad et al.
patent: 5874479 (1999-02-01), Martin
patent: 6346519 (2002-02-01), Petrus
patent: 6391864 (2002-05-01), Stone
patent: 6417227 (2002-07-01), Lord et al.
patent: 6458777 (2002-10-01), Sonis et al.
patent: 0 244 178 (1987-11-01), None
patent: WO 99/52508 (1999-10-01), None
patent: WO 00/64436 (2000-11-01), None
The Merck Index, 13th Ed. p. 778, Merck & Co., Inc. © 2001.
Mosby's GENRx, 8th Ed., pp. II-759-II-763 Mosby Year Book, Inc. © 1998.
Lozada and Altman, “Chondroprotection in Osteoarthritis” Bulletin on the Rheumatic Diseases, vol. 46(7), pp. 5-7 (Nov. 1997).
Steere, “Diagnosis and Treatment of Lyme Arthritis” Medical Clinics of North America, vol. 81(1), pp. 179-194 (Jan. 1997).
Frankel et al, “Oral Crohn's disease: Report of two cases in brothers with metallic dysgeusia and a review of the literature” Journal of the American Academy of Dermatology, vol. 12(2 Pt. 1), pp. 260-268 (Feb. 1985).
Sobolev et al, “Tetracycline Combination with Glucosamine in the Treatment of Bile Duct Inflammation” Antibiotiki, vol. 12(5), pp. 436-438 (1967).
Fomin et al., “Antibacterial Action of Dimethyl Sulfoxide” Antibiotiki, vol. 19(8), pp. 745-748 (1974).
Provisional Application 60/077,977, filed Mar. 13, 1998.
Sobolev et al, “Tetracycline Combination with Glucosamine in the Treatment of Bile Duct Inflammation” Antibiotiki, vol. 12(5), pp. 436-438 (1967). English Translation.
Fomin et al, “Antibacterial Action of Dimethyl Sulfoxide” Antibiotiki, vol. 19(8), pp. 745-748 (1974). English Translation.
“Periodontal Disease” monograph from Health A to Z website. © Oct. 17, 2005.
Truelove and Jewell, “Intensive Intravenous Regimen for Severe Attacks of Ulcerative Colitis”Lancet, vol. 1 (7866) , pp. 1067-1070 (Jun. 1, 1974).
Krause and Mahan, Food Nutrition and Diet Therapy: A Textbook of Nutritional Care, 7thedition, pp. 40-51 and 850-876, W.B. Saunders Company (1984).
Beluzzi, et al., “Effects of New Fish Oil Derivative on Fatty Acid Phospholipid-Membrane Pattern in a group of Crohn's Disease Patients”, Digestive Diseases and Sciences, vol. 39(12), pp. 2589-2594 (Dec. 1994).
Product Alert: “Integris Everlasting” mfgd. By Health Solutions (Dec. 22, 1997).
Cochran and Dent, “Cetyl-Myristoleate—A Unique Natural Compound Valuable in Arthritis Conditions”, pp. 70-74, Townsend Letter for Doctors and Patients (Jul. 1997).
Cochran, “Dr. Chuck Cochran Discusses Arthritis and Cetyl Myristoleate”, entire publication (© 1996).
Siemandi, “The effect of cis-9-cetyl myristoleate (cmo) and ajunctive therapy on the course of arthritic episodes in patients with various auto-immune diseases characterized by the common terminology, “arthritis”. . . ”, Manuscript, pp. 1-6 (1997).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10thedition, McGraw-Hill, pp. 1047 and 1048 (2002).
Websters's II New Riverside University Dictionary, Houghton Mifflin Co., pp. 127 (1994).
The Merck Index, 11thedition, Merck & Co., Rahway, NJ, USA, pp. 26, 870, 4353 (1989).
Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 9thedition, J.B. Lippincott Co., pp. 723-732 (1991).
Greenwald, et al., “Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Fluribiprofen, Ameliorate Bone Damage”, J. Rheumatology, vol. 19(6), pp. 927-938 (1992).
Simon, et al., “Preliminary Study of the Safety and Efficacy of SC-58635, a Novel Cyclooxygenase 2 Inhibitor”, Arthritis and Rheumatism, vl. 41(9), pp. 1591-1602 (1998).
Altman, et al., “Intraarticular Sodium Hyaluronate (Hyalgan) in the Treatment of Patients with Osteoarthritis of the Knee: A Randomized Clinical Trial”, J. Rheumatology, vol. 25(11), pp. 2203-2212 (1998).
Levin Bruce H.
Tucker Zachary C.
LandOfFree
Methods and compositions for treatment of inflammatory disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of inflammatory disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of inflammatory disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536973